Shares of Quotient (NASDAQ:QTNT) were unchanged in pre-market trading after the company reported Q4 results.
Earnings per share rose 24.39% year over year to ($0.31), which beat the estimate of ($0.34).
Revenue of $8,700,000 rose by 5.06% from the same period last year, which beat the estimate of $7,930,000.
Quotient hasn't issued any earnings guidance for the time being.
Quotient hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Jun 09, 2020
Time: 08:00 AM
ET Webcast URL: https://www.quotientbd.com/media/events-and-presentations
Company's 52-week high was at $11.30
52-week low: $2.40
Price action over last quarter: down 10.13%
Quotient Ltd is a commercial-stage diagnostics company. It is involved in the business of provision of tests with an initial focus on blood grouping and serological disease screening. The company develops and commercializes Mosaiq automation platform. Its product portfolio includes Red cell reagents, Antisera, Specialty products, Specialty kits etc. The firm operates in Edinburgh, Scotland, Eysins, Switzerland and Newton, Pennsylvania. It derives the majority of its revenue from the United States.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.